Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Roche’s Ocrevus set to top $7.6bn in sales by 2028, backed by new dosing approval in the MS market

Following the news that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS); Sarah Elsayed, MBA, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Ocrevus boasts a superior pharmacological profile in the MS market due to its high efficacy, good tolerability and convenient six-month dosing regimen via intravenous infusion (IV). The new FDA approval will further improve […]
Read more

JDRF’s T1Detect population screening could revolutionize type 1 diabetes awareness and management

Juvenile Diabetes Research Foundation (JDRF) recently announced the launch of its ground-breaking screening initiative for type 1 diabetes (T1D), T1Detect, which aims to make early detection of T1D easier and more accessible to the broader population. This initiative will revolutionize awareness and management of the disease going forward as it will open up the market for preventative therapeutics and other disease-modifying therapies, says GlobalData, a leading data and analytics company. Samisha Khangaonkar, Pharma Analyst at GlobalData, comments: “Approximately 85% […]
Read more

Established players in Japan’s immunology market dominate branded digital marketing space, finds GlobalData

The Japanese immunology market is highly competitive with many innovator products available for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn’s disease (CD), and ankylosing spondylitis (AS) indications. Across these indications, the branded support available for initially approved therapies dominate the digital marketing space compared […]
Read more

COVID-19 expedites India’s focus on innovation within pharma, says GlobalData

The COVID-19 pandemic has pushed India to expedite focus on pharma research and development (R&D) to become more independent. The hope of getting indigenous COVID-19 vaccines has boosted the government’s confidence towards indigenous research and development and this momentum should continue, says GlobalData, a leading data analytics and research company. India is expected to unveil a […]
Read more

AbbVie’s Rinvoq tops defending champion Dupixent in atopic dermatitis

The recently demonstrated superiority of AbbVie’s Rinvoq (upadacitinib) versus Regeneron and Sanofi’s Dupixent (dupilumab) across primary and all secondary endpoints in the Phase IIIb Heads Up study may well showcase its potential to usurp Dupixent as the gold standard of atopic dermatitis (AD) therapy, but it is the speed of which the efficacy became evident in patients that shows the drug’s real promise, says GlobalData, a leading data and […]
Read more

US cannot wait on vaccines to control COVID-19

Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally; Kasey Fu, Director of Epidemiology at GlobalData, a leading data and analytics company, offers her view: “News that the US has hit another […]
Read more

The US has the largest number of late-stage COVID-19 vaccines in development

With Pfizer/BioNTech’s COVID-19 vaccine becoming the first mRNA vaccine in the world to receive emergency use approval by the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA), the race is on for other bio/pharma companies with COVID-19 candidates to seek out authorization from regulators within the coming weeks, says GlobalData, a leading data and analytics company. Sharon Cartic at GlobalData comments: “The US has the largest number of COVID-19 vaccines in late-stage clinical development among the top pipeline geographies, with the EU following closely behind. The US currently has a total of 12 COVID-19 vaccines in Phases II and III, […]
Read more

Slovakia’s national COVID-19 testing program was only a temporary solution

Following Slovakia’s national testing program from 31 October – 1 November, where two-thirds of the population were tested and the number of new daily cases dropped substantially, Slovakia was applauded for its efforts and held up as a possible solution to other European countries, says GlobalData, a leading data and analytics company. Katie Wrenn, Pharma Analyst at GlobalData, comments: “The recent weeks have seen a slight rise in new cases, and though this increase is minimal, if cases continue […]
Read more

Immune checkpoint inhibitors will represent 47% of the 5EU gastric and gastroesophageal market by 2029

The lack of approved immune checkpoint inhibitors (ICI) in the gastric and gastroesophageal adenocarcinoma (G/GEJAC) market in the *5EU is expected to significantly enhance the revenue of Opdivo and Keytruda following their upcoming label expansions. In fact, GlobalData’s latest report, ‘Gastric and Gastroesophageal Junction Adenocarcinoma Global Drug Forecast and Market Analysis to 2029’, notes that these […]
Read more

Galapagos Phase IIA PINTA IPF topline study results are cause for cautious optimism

Galapagos recently reported positive topline results from its Phase IIA PINTA clinical trial investigating the use of 100 mg GLPG1205 for the treatment of idiopathic pulmonary fibrosis (IPF). Although the trial had a promising result in a disease with high unmet clinical need, the real test for the drug will come in the form of larger trials and subsequent statistical evaluation, according to GlobalData a leading data […]
Read more

An Estimated 60% of All Asthma Cases Go Undiagnosed in the UK

Currently in the UK, there are over nine million lifetime diagnosed prevalent cases of asthma and approximately 13 million undiagnosed asthma patients, says GlobalData, a leading data and analytics company. Bahram Hassanpourfard, Epidemiologist Analyst at GlobalData, comments: “The testing limitations of asthma in primary care services likely result in a high number of undiagnosed patients. NHS […]
Read more

Janssen’s PP6M set to be promising treatment to increase compliance rates in schizophrenia

Following the news that Janssen has submitted a Marketing Authorisation Extension to the European Medicines Agency (EMA) for its product paliperidone palmitate 6-Monthly (PP6M) for the treatment of schizophrenia in adults; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Antipsychotic medication are the most prescribed in schizophrenia, […]
Read more

Canada sets out COVID-19 plans to vaccinate a majority by September 2021

Following Prime Minister Justin Trudeau’s announcement of Canada’s vaccination schedules; James Spencer, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “With the recent announcement of several potential COVID-19 vaccines one after another, countries around the world have been scrambling to put together their vaccine plans. “Trudeau stated that he expects […]
Read more
1 … 74 75 76 77 78 … 110